Table 1.
The characteristics of patients with healthcare-associated bloodstream infections due to multidrug-resistant Acinetobacter baumannii in the COVID-19 intensive care units at the Dubrava University Hospital during the second wave of the COVID-19 pandemic (1 October 2020–28 February 2021) (N = 106).
| Variable | N (%) |
|---|---|
| Age, median (range), in years | 72 (89–48) |
| Male (%) | 83 (78.3) |
| Comorbidity * | |
| Without comorbidity | 28 (26.4) |
| With comorbidity | 78 (73.6) |
| Diabetes mellitus | 40 (37.7) |
| Peripheral artery disease | 22 (20.7) |
| Coronary artery disease | 19 (17.9) |
| Cardiomyopathy | 12 (11.3) |
| Neurologic disease | 11 (10.4) |
| Chronic renal insufficiency | 9 (8.5) |
| COPD | 6 (5.7) |
| Characteristics at ICU admission | |
| Duration of disease prior to admission, mean (range), in days | 10 (1–36) |
| Bilateral pneumonia | 99 (93.4) |
| PaO2/FiO2 (median) | 67.9 |
| SOFA score (median) | 4 |
| APACHE II score (median) | 13 |
| SAPS II score (median) | 30.5 |
| Treatment and outcome | |
| Antiviral therapy | 21 (19.8) |
| Immunomodulatory therapy | 65 (61.3) |
| ATB treatment prior to BSI: | 99 (93.4) |
| Ceftriaxone | 57 (53.8) |
| Meropenem | 24 (22.6) |
| Piperacillin/tazobactam | 18 (16.9) |
| Amoxicillin/clavulanic acid | 12 (11.3) |
| Duration of ATB treatment for BSI (median days, mean) | 6 (8.3) |
| ATB treatment of BSI | |
| Colistin monotherapy | 47 (44.3) |
| Colistin in combination with other antibiotics | 29 (27.3) |
| ATB therapy not including colistin | 6 (5.7) |
| Outcome | |
| Discharged from hospital | 15 (14.2) |
| Fatal outcome in ICU | 91 (85.8) |
* Some patients had more than one comorbidity; ATB—antibiotic; BSI—bloodstream infection; COPD—chronic obstructive pulmonary disease; ICU—intensive care unit.